MX2024002581A - Lou064 para el tratamiento de la esclerosis multiple. - Google Patents
Lou064 para el tratamiento de la esclerosis multiple.Info
- Publication number
- MX2024002581A MX2024002581A MX2024002581A MX2024002581A MX2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A
- Authority
- MX
- Mexico
- Prior art keywords
- lou064
- multiple sclerosis
- treatment
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- CUABMPOJOBCXJI-UHFFFAOYSA-N remibrutinib Chemical compound CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C CUABMPOJOBCXJI-UHFFFAOYSA-N 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240444P | 2021-09-03 | 2021-09-03 | |
| US202163282363P | 2021-11-23 | 2021-11-23 | |
| US202263304106P | 2022-01-28 | 2022-01-28 | |
| US202263353866P | 2022-06-21 | 2022-06-21 | |
| US202263369008P | 2022-07-21 | 2022-07-21 | |
| PCT/IB2022/058205 WO2023031840A1 (en) | 2021-09-03 | 2022-09-01 | Lou064 for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002581A true MX2024002581A (es) | 2024-03-20 |
Family
ID=83438454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002581A MX2024002581A (es) | 2021-09-03 | 2022-09-01 | Lou064 para el tratamiento de la esclerosis multiple. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240350489A1 (https=) |
| EP (1) | EP4395779A1 (https=) |
| JP (2) | JP7564347B2 (https=) |
| KR (1) | KR20240055038A (https=) |
| AU (1) | AU2022337087A1 (https=) |
| CA (1) | CA3229887A1 (https=) |
| IL (1) | IL310975A (https=) |
| MX (1) | MX2024002581A (https=) |
| TW (1) | TW202310841A (https=) |
| WO (1) | WO2023031840A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| US20260027100A1 (en) * | 2022-05-13 | 2026-01-29 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad) |
| CA3260242A1 (en) * | 2022-06-24 | 2023-12-28 | Merck Patent Gmbh | TREATMENT REGIMEN FOR AUTOIMMUNE AND INFLAMMATORY DISEASES |
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197080A1 (en) * | 2010-08-02 | 2013-08-01 | Sanofi | Use of teriflunomide for treating multiple sclerosis |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3738084A4 (en) * | 2018-01-08 | 2021-11-17 | G1 Therapeutics, Inc. | SUPERIOR G1T38 DOSING SCHEMES |
| CN117285467A (zh) * | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| RS67141B1 (sr) | 2019-05-23 | 2025-09-30 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije |
| CN113840821A (zh) | 2019-05-23 | 2021-12-24 | 诺华股份有限公司 | Btk抑制剂的晶型 |
| BR112021023110A2 (pt) | 2019-05-23 | 2022-04-12 | Novartis Ag | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton |
| WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| MX2023008671A (es) * | 2021-01-26 | 2023-09-25 | Novartis Ag | Composicion farmaceutica. |
| BR112023017648A2 (pt) * | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk |
-
2022
- 2022-09-01 JP JP2023517239A patent/JP7564347B2/ja active Active
- 2022-09-01 US US18/685,551 patent/US20240350489A1/en active Pending
- 2022-09-01 CA CA3229887A patent/CA3229887A1/en active Pending
- 2022-09-01 KR KR1020247010451A patent/KR20240055038A/ko active Pending
- 2022-09-01 AU AU2022337087A patent/AU2022337087A1/en active Pending
- 2022-09-01 TW TW111133216A patent/TW202310841A/zh unknown
- 2022-09-01 WO PCT/IB2022/058205 patent/WO2023031840A1/en not_active Ceased
- 2022-09-01 EP EP22777001.3A patent/EP4395779A1/en active Pending
- 2022-09-01 IL IL310975A patent/IL310975A/en unknown
- 2022-09-01 MX MX2024002581A patent/MX2024002581A/es unknown
-
2024
- 2024-09-26 JP JP2024167085A patent/JP2024178420A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7564347B2 (ja) | 2024-10-08 |
| US20240350489A1 (en) | 2024-10-24 |
| JP2023542878A (ja) | 2023-10-12 |
| JP2024178420A (ja) | 2024-12-24 |
| TW202310841A (zh) | 2023-03-16 |
| EP4395779A1 (en) | 2024-07-10 |
| KR20240055038A (ko) | 2024-04-26 |
| IL310975A (en) | 2024-04-01 |
| CA3229887A1 (en) | 2023-03-09 |
| WO2023031840A1 (en) | 2023-03-09 |
| AU2022337087A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| MX2024008886A (es) | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| NI202100047A (es) | COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE alfa1-ANTITRIPSINA | |
| MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
| DOP2018000183A (es) | Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos | |
| AR112101A1 (es) | Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll). | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer |